| Schedule of Acquisition-related Restructuring, impairments |
Acquisition-related charges (gains), impairment and other for the years ended December 31, 2022, 2021 and 2020 are summarized below (in thousands): | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | 2022 | | 2021 | | 2020 | | Severance-related expenses | $ | 4,494 | | | $ | 26,371 | | | $ | — | | | Acquisition-related fees | 1,032 | | | 10,963 | | | — | | | Other acquisition expenses | 5,719 | | | 3,566 | | | 150 | | | Total acquisition-related charges | 11,245 | | | 40,900 | | | 150 | | | Flexion contingent consideration | (18,292) | | | 1,174 | | | — | | | MyoScience contingent consideration | (11,184) | | | (2,163) | | | 5,204 | | | Impairment of acquired IPR&D | 26,134 | | | — | | | — | | | Termination of license agreement | 3,000 | | | — | | | — | | | Nuance Biotech Co. Ltd. agreement dissolution costs | — | | | 3,000 | | | — | | | Discontinuation of DepoCyt(e) | — | | | — | | | (188) | | | Total acquisition-related charges (gains), impairment and other | $ | 10,903 | | | $ | 42,911 | | | $ | 5,166 | |
|